1.305USD-5.43%Mkt Cap: 79.34M USDP/E: —Last update: 2026-06-01
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap79.34M USD
Enterprise Value44.02M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-22.40M USD
Revenue/Share—
Last Price1.305 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)1.24
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.03
EPS (TTM)-0.68
EPS (Forward)1.12
52W Range
0.870019% of range3.190
52W High3.190 USD
52W Low0.8700 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-942.65%
ROA-230.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.84M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-14.93%
Net Debt-34.41M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio5.59
Quick Ratio5.44
Book Value/Sh0.4580 USD
Cash/Share0.5660 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)12.13 USD
Target Range10.27 USD – 14.00 USD
# Analysts2
Ownership
Shares Out.60.80M
Float51.46M
Insiders14.26%
Institutions21.58%
Short Interest
Short Ratio4.7d
Short % Float5.06%
Short % Out.4.64%
Shares Short2.82M
Short (prev mo.)2.83M
Technical
SMA 501.332 (-2.0%)
SMA 2001.517 (-14.0%)
Beta0.23
S&P 52W Chg27.94%
Avg Vol (30d)554.63K
Avg Vol (10d)464.05K
Technical Indicators
RSI (14)56.3
MACD-0.0107
MACD Signal-0.0216
MACD Hist.+0.0108
BB Upper1.402 USD
BB Middle1.313 USD
BB Lower1.225 USD
BB Width13.44%
ATR (14)0.0885 USD
Vol Ratio (20d)2.06x